Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Table 3 Cardiovascular adverse events in participants ≥60 years of age with a cardiovascular medical history

CV AEs, n (%)	Quarterly fremanezumab	Monthly fremanezumab		Placebo
CV AEs, n (%)	(CM/EM: 675 mg/PBO/PBO)	(EM: 225/225/225 mg)	(CM: 675/225/225 mg)	Placebo
*Participants with CV medical history*	*(n = 30)*	*(n = 6)*	*(n = 14)*	*(n = 23)*
≥1 CV AE	1 (3)	0	2 (14)	1 (4)
AEs with incidence ≥1 participant in any treatment/dose group
Palpitations	0	0	1 (7)	1 (4)
Hypertensive crisis	0	0	1 (7)	0
Supraventricular tachycardia	1 (3)	0	0	0
*Participants without CV medical history*	*(n = 44)*	*(n = 40)*	*(n = 32)*	*(n = 57)*
≥1 CV AE	0	0	2 (6)	0
AEs with incidence ≥1 participant in any treatment/dose group
Hot flush	0	0	1 (3)	0
Hypertension	0	0	1 (3)	0

CM, chronic migraine; EM, episodic migraine; PBO, placebo; CV, cardiovascular; AE, adverse event

ISSN: 1129-2377